Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib

J Oncol Pract. 2019 May;15(5):293-295. doi: 10.1200/JOP.18.00708. Epub 2019 Apr 2.

Authors

Tiffany Seto¹, Deepti Pujare¹, Mee-Na Song¹, Jason Lee¹, Ryan Huber¹, Danny Sam¹, Minggui Pan^{1

2}

Affiliations

¹ 1 Kaiser Permanente, Santa Clara, CA.
² 2 Kaiser Permanente Division of Research, Oakland, CA.

PMID: 30939057
DOI: 10.1200/JOP.18.00708

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics*
Adenocarcinoma / metabolism
Adenocarcinoma / pathology
Adult
BRCA1 Protein / genetics*
Female
Germ-Line Mutation*
Humans
Indoles / administration & dosage
Indoles / adverse effects
Indoles / therapeutic use*
Poly(ADP-ribose) Polymerase Inhibitors / administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Positron-Emission Tomography
Sequence Deletion*
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / genetics*
Urinary Bladder Neoplasms / metabolism
Urinary Bladder Neoplasms / pathology

Substances

BRCA1 Protein
BRCA1 protein, human
Indoles
Poly(ADP-ribose) Polymerase Inhibitors
rucaparib

Supplementary concepts

Urachal adenocarcinoma